close
close

Arrowhead Pharmaceuticals Presents New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome Page 1

Posted on by Vaseline
Arrowhead Pharmaceuticals Presents New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome Page 1

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present new Phase 3 clinical data from the PALISADE study of plozasiran (ARO-APOC3) at the European Society of Cardiology (ESC) 2024 Congress, being held in London from August 30 to September 2, 2024. The company will also host a virtual event for analysts and investors on September 3, 2024 at 8:00 a.m. EDT.

Below you will find details about the ESC presentation.

Related Posts